NCT00077987

Brief Summary

Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Dec 2003

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2003

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 13, 2004

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 18, 2004

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2005

Completed
Last Updated

January 11, 2007

Status Verified

October 1, 2005

First QC Date

February 13, 2004

Last Update Submit

January 9, 2007

Conditions

Colorectal Neoplasms

Outcome Measures

Primary Outcomes (1)

  • Anti-tumor efficacy

Secondary Outcomes (1)

  • Tumor control survival safety

Interventions

SU011248DRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Metastatic colorectal cancer
  • Failed selected cancer therapies in the past.

You may not qualify if:

  • Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Sunitinib

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

PyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 13, 2004

First Posted

February 18, 2004

Study Start

December 1, 2003

Study Completion

April 1, 2005

Last Updated

January 11, 2007

Record last verified: 2005-10